Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: news events forteo® post market osteosarcoma surveillance program real world data contributes
… studies to help our clients develop strategies in the CNS market and to develop and gain market access for products to treat CNS diseases and … Database analyses using cross-sectional and longitudinal data sources Decision-analytic models (cost effectiveness, …
… equity initiatives to inform their research and enhance data acquisition to address health disparities. But where to … and how these best practices can strengthen demographic data-gathering methods. From this presentation, you will …
… at UNC Chapel Hill, metabolic pathway targeting in osteosarcoma cells over summer internships at The …
… a retrospective analysis of US health insurance claims data. Shavit A, Dolin P, Kielar D, Keogh KA, Rowell J, …
… Kidney Foundation Spring Clinical Meetings. Pooled data analysis of the long-term effect of Tolvaptan in …
… You’ll hear our experts in patient-centered outcomes and market access strategy have a conversation about their … failures, and the lessons we've learned Related Services Market Access and Outcomes Strategy Patient-Centered Outcomes …
Early Dialog with NICE and EUnetHTA See the research: Early dialogue with NICE and EUnetHTA: a UK perspective in a politically uncertain ERA Heyes A, Millar L Transcript: We have conducted a review of publicly available information on scientific advice …
… non-high all-cause costs: an analysis of insurance claims data. Xu X, Kwiatek J, Chehade M, Aceves S, Maslova E, Kielar …
… RTI-HS, including Surveys and Observational Studies, Market Access and Outcome Strategies, and Health Economics. …
… therapies for Alzheimer’s disease, or AD, enter the market, economic evaluations are going to play a key role in … patient-relevant outcomes from short-term clinical trial data. Motivated by this challenge, and by the goal of … benchmark scenario using hypothetical clinical trial data for a treatment for early AD. We first compared the …